Featured Research

from universities, journals, and other organizations

Research Holds Promise For Herpes Vaccine

Date:
October 16, 2006
Source:
Montana State University
Summary:
A study by a Montana State University researcher suggests a new avenue for developing a vaccine against genital herpes and other diseases caused by herpes simplex viruses.

Montana State University virologist Bill Halford has successfully tested a herpes vaccine in mice. His research may lead to a human vaccine against genital herpes, which is carried by an estimated 55 million Americans. (MSU photo by Jay Thane)

A study by a Montana State University researcher suggests a new avenue for developing a vaccine against genital herpes and other diseases caused by herpes simplex viruses.

In a study published earlier this year in the Virology Journal, MSU virologist William Halford showed that mice vaccinated with a live, genetically-modified herpes simplex virus type 1 (HSV-1) showed no signs of disease 30 days after being exposed to a particularly lethal "wild-type" strain of the virus.

In contrast, a second group of mice that received a more conventional vaccine died within six days of being exposed to the same "wild-type" strain.

"We have a clear roadmap for producing an effective live vaccine against genital herpes," said Halford, who works in MSU's Department of Veterinary Molecular Biology. "Although my studies were performed with HSV-1, the implications for HSV-2-induced genital herpes are clear. Overall the two viruses are about 99 percent genetically identical."

An estimated 55 million Americans carry herpes simplex virus type 2 (HSV-2), which causes genital herpes. Infection is life-long. Approximately 5 percent of those with genital herpes - 2 million to 3 million Americans - suffer outbreaks one to four times annually. A vaccine offering life-long protection does not exist.

The key to Halford's research was understanding how the herpes simplex virus overcame the body's natural defenses.

A cell infected with the herpes simplex virus sends a warning to neighboring cells. This warning -- an interferon response -- causes neighboring cells to enter "an anti-viral state" akin to putting on a suit of armor, Halford said.

However, herpes produces a protein, ICP0, that tricks every infected cell into destroying its own armor. Once the cell's armor is gone, the virus can propagate itself and spread to other cells, which are in turn tricked into lowering their defenses.

In his research, Halford created a vaccine where the genetic instructions that make ICP0 were disrupted. Without instructions on how to do its clever ICP0 trick, the virus can still establish an infection in animals, but the spread of the virus is stopped long before disease can occur.

"In short, we can disarm the virus such that it is absolutely unable to cause disease, but is still remarkably potent as a vaccine," Halford said.

In a human vaccine, the genetic instructions for ICP0 would actually be removed, creating an "attenuated," or weakened virus. The rest of the herpes simplex virus' genetic code would remain intact. Measles, mumps, rubella, polio and yellow fever vaccines are all made from attenuated viruses.

Research in recent decades has focused on subunit vaccines, which are made from one piece of a virus (a protein subunit). Subunit vaccines are safer than attenuated virus vaccines because the subunit cannot replicate or cause disease. However, subunit vaccines have proven ineffective in protecting people against persistent infections like genital herpes and AIDS, Halford said.

"From a theoretical standpoint, subunit vaccines are poor mimics of a natural virus infection," Halford said. "There's not enough there for our immune systems to build a protective response against the actual virus."

Halford, 38, is aware that his approach is controversial.

"This is where I'm young enough that I don't know how long it can take to swing popular opinion among scientists and clinicians," he said. "I would hope that in five to six years the scientific community would be willing to seriously consider these proposals."

Halford hopes to find a commercial partner or secure government funding to advance his research toward a human vaccine.

"I'd like to take this concept from the chalkboard to the clinics," he said.


Story Source:

The above story is based on materials provided by Montana State University. Note: Materials may be edited for content and length.


Cite This Page:

Montana State University. "Research Holds Promise For Herpes Vaccine." ScienceDaily. ScienceDaily, 16 October 2006. <www.sciencedaily.com/releases/2006/10/061013201826.htm>.
Montana State University. (2006, October 16). Research Holds Promise For Herpes Vaccine. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2006/10/061013201826.htm
Montana State University. "Research Holds Promise For Herpes Vaccine." ScienceDaily. www.sciencedaily.com/releases/2006/10/061013201826.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins